NASDAQ
0.74USD
+0.03 (+3.83%)
We have scored 4 news catalysts on Standard BioTools Inc. (LAB) over the past 12 months. The biggest single-day move next to one of them came Jun 9, 2026, when LAB closed +10.3%: “Standard BioTools Inc. (LAB) Discusses Merger and Strategic Rationale Prepared Remarks Transcript”. Coverage across the window leans positive (average ticker sentiment +0.20). Most of the impact sits in short squeeze potential and factor value.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
289.9M
P/E
—
EPS
—
Beta
1.37
52W range
0.6251-1.72
Day range
0.71–0.74
Open
0.72
Prev close
0.71
Volume
1.6M
Avg volume
2.8M
Dividend
0.00
IPO
2011-02-10
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Standard BioTools Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for LAB: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
